Sugi Predict

Sugi Predict / Compounds / SCHEMBL9999452

SCHEMBL9999452

SCHEMBL9999452

CC(C)(C)OC(=O)N1CCN(c2ncc(Br)cc2F)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 4/20 0.50
▸ KIT P10721 2/20 0.45
▸ CKS1B P61024 2/20 0.45
▸ SKP1 P63208 2/20 0.45
▸ SKP2 Q13309 2/20 0.45
▸ ALK Q9UM73 1/20 0.44
▸ NR1H2 P55055 1/20 0.43
▸ NR1H3 Q13133 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ GRIA1 P42261 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ USP30 Q70CQ3 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ DPP4 P27487 1/20 0.42
▸ CYP3A4 P08684 1/20 0.41
▸ CYP3A5 P20815 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31342038 0.89 OPRK1 (0.50) GPR119DPP4
SCHEMBL2366669 0.88 KIT (0.47) GPR119KITCKS1BSKP1SKP2
SCHEMBL2420435 0.88 GPR119 (0.52) GPR119KITCKS1BSKP1SKP2
SCHEMBL30893588 0.88 GPR119 (0.52) GPR119KITCKS1BSKP1SKP2
SCHEMBL24880671 0.87 CYP11B2 (0.45) GPR119USP30
SCHEMBL30112430 0.87 CYP11B2 (0.45) GPR119USP30
SCHEMBL21551198 0.86 GPR119 (0.54) GPR119KITCKS1BSKP1SKP2
SCHEMBL30931849 0.86 GPR119 (0.54) GPR119KITCKS1BSKP1SKP2
SCHEMBL24125815 0.86 GPR119 (0.51) GPR119KITCKS1BSKP1SKP2
SCHEMBL908053 0.86 RET (0.49) GPR119KITCKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 — — EP disclosed
US-12319683-B2 Azabenzimidazole compounds and pharmaceutical NIPPON SHINYAKU CO., LTD. (JP) 2025-06-03 — — US disclosed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 — — US disclosed
WO-2024215809-A2 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-10-17 — — WO disclosed
EP-3792260-B1 AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL NIPPON SHINYAKU CO LTD (JP) 2024-09-11 — — EP disclosed
CN-112368282-B Azabenzimidazole compounds and medicaments 日本新药株式会社 2023-10-13 — — CN disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-20140329829-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF SHIONOGI & CO., LTD. (JP) 2014-11-06 — — US disclosed
WO-2014006554-A1 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-01-09 — — WO disclosed
US-20130123239-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF PURDUE PHARMA L.P. 2013-05-16 — — US disclosed
US-20130123239-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF PURDUE PHARMA L.P. 2013-05-16 — — US disclosed
US-20130123239-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF PURDUE PHARMA L.P. 2013-05-16 — — US disclosed
EP-2585446-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF Shionogi&Co., Ltd. (JP) 2013-05-01 — — EP disclosed
WO-2012176061-A9 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF PURDUE PHARMA L.P. (US) 2013-03-14 — — WO disclosed
WO-2012176061-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF PURDUE PHARMA L.P. (US) 2012-12-27 — — WO disclosed
WO-2011162409-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF SHIONOGI & CO., LTD. (JP) 2011-12-29 — — WO disclosed
WO-2011162409-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF SHIONOGI & CO., LTD. (JP) 2011-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559492-B2 BRAF degraders BRAF, NRAS, HRAS GPR119 1556/4885KIT 1952/4885CKS1B 68/4885
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 GPR119 4038/4885KIT 1988/4885CKS1B 543/4885
US-20130123239-A1 COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF TRPV1, TRPA1, TRPV2 GPR119 84/4885KIT 228/4885CKS1B 3222/4885
US-20140329829-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF TRPV1, TRPA1, TRPV3 GPR119 32/4885KIT 328/4885CKS1B 3658/4885
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR GPR119 1085/4885KIT 1069/4885CKS1B 77/4885
US-12319683-B2 Azabenzimidazole compounds and pharmaceutical PAM, CHRM3, AZI2 GPR119 559/4885KIT 1391/4885CKS1B 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.